The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis.

BACKGROUND: Despite the inevitability of disease progression in amyotrophic lateral sclerosis, there is a high degree of prognostic heterogeneity in all subtypes. Some bulbar-onset (BO) patients may develop rapid anarthria yet remain ambulant for a prolonged period, whereas others progress rapidly,...

ver descrição completa

Detalhes bibliográficos
Main Authors: Turner, M, Scaber, J, Goodfellow, J, Lord, M, Marsden, R, Talbot, K
Formato: Journal article
Idioma:English
Publicado em: 2010
_version_ 1826264479607816192
author Turner, M
Scaber, J
Goodfellow, J
Lord, M
Marsden, R
Talbot, K
author_facet Turner, M
Scaber, J
Goodfellow, J
Lord, M
Marsden, R
Talbot, K
author_sort Turner, M
collection OXFORD
description BACKGROUND: Despite the inevitability of disease progression in amyotrophic lateral sclerosis, there is a high degree of prognostic heterogeneity in all subtypes. Some bulbar-onset (BO) patients may develop rapid anarthria yet remain ambulant for a prolonged period, whereas others progress rapidly, with early generalisation of motor weakness to the limbs and respiratory muscles. Diagnostic delay is a common occurrence in ALS, and many BO patients report having attended other specialist clinics prior to diagnosis. METHODS: A retrospective descriptive study of BO ALS patients seen in a tertiary clinic over a six year period. RESULTS: Forty-nine BO ALS patients were studied. Median survival from symptom onset was 27 months (range 6-84). 63% of subjects were female and the mean age at symptom onset was 68 years. Half had been referred to another speciality prior to diagnosis, either otolaryngology or stroke clinics, but this did not influence diagnostic latency or survival. Emotionality was reported in 45% of patients. Neurophysiological assessment was performed in 80%, brain imaging recorded in 69%, and antibody testing for myasthenia gravis in 22%. The median time to symptomatic progression beyond the bulbar region was approximately 1 year, with equal proportions progressing to the upper or lower limbs. The median interval from onset to anarthria was 18 months, and to loss of ambulation 22 months. There was a close correlation between the two (r(2)=0.6) and median survival from loss of ambulation was only 3 months. Gastrostomy was carried out in 78% of patients with a median time of 13 months from symptom onset, and 3 months from diagnosis. Median survival from gastrostomy was 10 months. CONCLUSIONS: Survival in bulbar-onset ALS is highly variable. Half of the patients were referred to an inappropriate clinic prior to diagnosis. The time interval to the development of anarthria predicted the timing of subsequent loss of ambulation accurately from which survival may then be only a few months.
first_indexed 2024-03-06T20:08:28Z
format Journal article
id oxford-uuid:29b72f41-9a5b-405e-a9e3-d0d5aef65b12
institution University of Oxford
language English
last_indexed 2024-03-06T20:08:28Z
publishDate 2010
record_format dspace
spelling oxford-uuid:29b72f41-9a5b-405e-a9e3-d0d5aef65b122022-03-26T12:20:48ZThe diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:29b72f41-9a5b-405e-a9e3-d0d5aef65b12EnglishSymplectic Elements at Oxford2010Turner, MScaber, JGoodfellow, JLord, MMarsden, RTalbot, KBACKGROUND: Despite the inevitability of disease progression in amyotrophic lateral sclerosis, there is a high degree of prognostic heterogeneity in all subtypes. Some bulbar-onset (BO) patients may develop rapid anarthria yet remain ambulant for a prolonged period, whereas others progress rapidly, with early generalisation of motor weakness to the limbs and respiratory muscles. Diagnostic delay is a common occurrence in ALS, and many BO patients report having attended other specialist clinics prior to diagnosis. METHODS: A retrospective descriptive study of BO ALS patients seen in a tertiary clinic over a six year period. RESULTS: Forty-nine BO ALS patients were studied. Median survival from symptom onset was 27 months (range 6-84). 63% of subjects were female and the mean age at symptom onset was 68 years. Half had been referred to another speciality prior to diagnosis, either otolaryngology or stroke clinics, but this did not influence diagnostic latency or survival. Emotionality was reported in 45% of patients. Neurophysiological assessment was performed in 80%, brain imaging recorded in 69%, and antibody testing for myasthenia gravis in 22%. The median time to symptomatic progression beyond the bulbar region was approximately 1 year, with equal proportions progressing to the upper or lower limbs. The median interval from onset to anarthria was 18 months, and to loss of ambulation 22 months. There was a close correlation between the two (r(2)=0.6) and median survival from loss of ambulation was only 3 months. Gastrostomy was carried out in 78% of patients with a median time of 13 months from symptom onset, and 3 months from diagnosis. Median survival from gastrostomy was 10 months. CONCLUSIONS: Survival in bulbar-onset ALS is highly variable. Half of the patients were referred to an inappropriate clinic prior to diagnosis. The time interval to the development of anarthria predicted the timing of subsequent loss of ambulation accurately from which survival may then be only a few months.
spellingShingle Turner, M
Scaber, J
Goodfellow, J
Lord, M
Marsden, R
Talbot, K
The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis.
title The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis.
title_full The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis.
title_fullStr The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis.
title_full_unstemmed The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis.
title_short The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis.
title_sort diagnostic pathway and prognosis in bulbar onset amyotrophic lateral sclerosis
work_keys_str_mv AT turnerm thediagnosticpathwayandprognosisinbulbaronsetamyotrophiclateralsclerosis
AT scaberj thediagnosticpathwayandprognosisinbulbaronsetamyotrophiclateralsclerosis
AT goodfellowj thediagnosticpathwayandprognosisinbulbaronsetamyotrophiclateralsclerosis
AT lordm thediagnosticpathwayandprognosisinbulbaronsetamyotrophiclateralsclerosis
AT marsdenr thediagnosticpathwayandprognosisinbulbaronsetamyotrophiclateralsclerosis
AT talbotk thediagnosticpathwayandprognosisinbulbaronsetamyotrophiclateralsclerosis
AT turnerm diagnosticpathwayandprognosisinbulbaronsetamyotrophiclateralsclerosis
AT scaberj diagnosticpathwayandprognosisinbulbaronsetamyotrophiclateralsclerosis
AT goodfellowj diagnosticpathwayandprognosisinbulbaronsetamyotrophiclateralsclerosis
AT lordm diagnosticpathwayandprognosisinbulbaronsetamyotrophiclateralsclerosis
AT marsdenr diagnosticpathwayandprognosisinbulbaronsetamyotrophiclateralsclerosis
AT talbotk diagnosticpathwayandprognosisinbulbaronsetamyotrophiclateralsclerosis